Roy Galvin compensation by year
HAEMONETICS Summary Compensation Table · all 2 fiscal years held| Component | FY2025 | FY2026 |
|---|---|---|
| Salary | $490,154 | $550,205 |
| Bonus | $0 | $0 |
| Stock awards | $1,011,733 | $1,473,137 |
| Option awards | $274,986 | $399,998 |
| Non-equity incentive | $378,263 | $586,960 |
| Pension and deferred compensation | $0 | $0 |
| All other | $41,204 | $28,818 |
| Total | $2,196,340 | $3,039,118 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: HAEMONETICS CORP DEF 14A filed June 9, 2026, accession 0000313143-26-000074, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2026 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 11,377 | $614,813 | — |
| RSU | 5,745 | $310,460 | — |
| RSU | 5,689 | $307,434 | — |
| RSU | 4,486 | $242,423 | — |
| RSU | 1,915 | $103,487 | — |
| RSU | 748 | $40,422 | — |
| RSU | 596 | $32,208 | — |
| Option | 12,317 | — | $70.31 |
| Option | 4,735 | — | $95.73 |
| Option | 1,316 | — | $83.96 |
| Option | 2,534 | — | $89.16 |
Per the Outstanding Equity Awards at Fiscal Year-End table in HAEMONETICS CORP's FY2026 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments HAEMONETICS discloses, by trigger · FY2026| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control and involuntary termination | $1,980,000 | $1,651,246 | $46,992 | $3,693,238 |
| Involuntary for cause | $0 | $0 | $0 | $0 |
| Voluntary resignation | $0 | $0 | $0 | $0 |
| Death | $0 | $1,086,483 | $0 | $1,086,483 |
| Disability | $0 | $1,086,483 | $0 | $1,086,483 |
| Involuntary termination without cause | $550,000 | $0 | $14,998 | $579,998 |
Per the Potential Payments Upon Termination or Change in Control table in HAEMONETICS CORP's FY2026 proxy. Estimates as the company printed them; a dash means it printed no figure.
HAEMONETICS’s named executive officers, FY2026
as the company reported each| Named executive officer | Role | FY2026 total |
|---|---|---|
| Christopher Simon | President and Chief Executive Officer | $12,044,701 |
| James D'Arecca | Executive Vice President, Chief Financial Officer | $3,623,016 |
| Michelle Basil | Executive Vice President, General Counsel | $3,409,543 |
| Frank Chan | Executive Vice President, Chief Operating Officer | $3,336,849 |
| Roy Galvin · this page | Executive Vice President, Chief Commercial Officer | $3,039,118 |
The full HAEMONETICS compensation record
free company briefThis page is one person within HAEMONETICS's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order HAEMONETICS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are HAEMONETICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat